camrelizumab with famitinib

Preclinical

SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

camrelizumab with famitinib is one of 20 therapeutic programs targeting Head and Neck Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Head and Neck CancerRecruiting

Head and Neck CancerPreclinical

Recruiting

Competition

Competitive Landscape

21 competitors in Head and Neck Cancer

#DrugCompanyPhaseTrials

Neurontin

VViatris Specialty LLC

Approved

4 2

Oxycontin

PProtega

Approved

2 3

MS Contin

HHikma Pharmaceuticals LLC

Approved

1 4

Toradol

JJavelin Pharmaceuticals

Approved

1 5

Marcaine

IInnocoll

Approved

1 6

Tylenol

KKenvue Brands

Approved

1 7

Tarceva

DDutch Society of Physicians for Pulmonology and Tuberculosis

Phase 2

6 8

Erbitux

IImclone

Phase 1

42 9

Opdivo

Bristol-Myers Squibb

Phase 1

9 10

RAD001

Novartis

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

PreclinicalRecruiting

Head and Neck Cancer

NCT07662681

Clinical

Trials by Indication[1]

Head and Neck Cancer1 trial

A Prospective, Multi-Cohort Study of Camrelizumab in Combination With Famitinib for the Treatment of Patients With Rare Head and Neck Malignancies

Recruiting·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Preclinical·NCT07662681·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for camrelizumab with famitinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for camrelizumab with famitinib. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

camrelizumab with famitinib

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Head and Neck Cancer1 trial

References

Drug Info

Quick Facts

Related News